

EUROPASS  
CURRICULUM VITAE



PERSONAL INFORMATION

Name: SIMONA GURZU  
Address: George Emil Palade University of Medicine, Pharmacy, Science and Technology  
38 Ghe Marinescu Street, 540193, Targu-Mures, Romania (UMFST)  
Contact: [simona.gurzu@umfst.ro](mailto:simona.gurzu@umfst.ro); [REDACTED]  
Nationality: Romanian  
Date of birth: [REDACTED] Gender: Female  
Web of science ID: <https://www.webofscience.com/wos/author/record/269087>  
Publons ID: <https://publons.com/researcher/1228066/simona-gurzu>  
ORCID ID: <https://orcid.org/0000-0003-3968-5118>  
Scopus ID: <https://www.scopus.com/authid/detail.uri?authorId=23473551900>  
SciProfiles ID: 0000-0003-3968-5118  
UEFISCDI/Brainmap ID: U-1700-036Q-0702 (<https://www.brainmap.ro/simona-gurzu>)  
Gogle Academic link: <https://scholar.google.com/citations?user=PVZruu0AAAAJ&hl=ro>  
Loop ID: 64628 (<https://loop.frontiersin.org/people/64628/overview>)  
Researchgate link: <https://www.researchgate.net/profile/Simona-Gurzu>  
RCA ID: <https://referencecitationanalysis.com/00000743>

DESIRED EMPLOYMENT/

OCCUPATIONAL FIELD - WORK EXPERIENCE

**Dates, Occupation, and positions held**

*The Romanian National Ministry of Education and Research*


From 2022- *Member in "Romanian Academy of Medical Sciences"*  
2017-2024 *Member in "National Board of Confirmation of PhD and Habilitation titles and other academic certificates" (CNATDCU)*  
2023 *Projects evaluator - PNRR-Dotari-2023 - Romanian Executive Agency for Higher Education, Research, Development, and Innovation (UEFISCDI)*  
2018-2023 *Projects Evaluator - Ministry of Innovation and Scientific Research (ANCS)*  
2019-2020 *Projects Evaluator - UEFISCDI*

*Romanian College of Physicians – Transylvania Branch*

2023-2029 Elected member in the Committee on Discipline

*George Emil Palade University of Medicine, Pharmacy, Sciences and Technology*

From April 2024 - **Dean - Faculty of Medicine in English - FMLE**  
2020-2024 **Vice-Dean – Faculty of Medicine in English - FMLE**  
<https://www.umfst.ro/medicina-engleza/organizare/conducerea-facultatii.html>  
**with extension in Hamburg, Germany – UMCH-** <https://edu.umch.de/en/our-team/>  
2023-2029 Member in the Senate of the University



2023-2029 Responsible for recognition of international certificates - Faculty of Medicine in English  
 From 2021 Coordinator of the Research Center for Oncopathology and Translational Medicine (CCOMT)  
 2021 **Founder of the Research Center for Oncopathology and Translational Medicine (CCOMT)**  
 From 2021- Member of the University Committee for Research and knowledge Exchange (UCRkE)  
 2020-2024 **Member in the General Scientific Council of PhD School (IOSUD)**  
 2020-2024 Head of Dean's Committee of Scientific Research and of Residency  
 2020-2024 Member in the Committee of Curricular activity  
 2020-2029 Member in the Council of Faculty of Medicine in English  
 2020-2022 Coordinator of COVID-related problems - Faculty of Medicine in English  
 From 2016- **Head of Department of Pathology**  
 2016-2029 Member in the Didactic Staff Council Department  
 2015-2021 **Head of the Microscopy Department - Research Center (CCAMF)**  
 From 2015- **Professor - Department of Pathology**  
 2014-2020 Responsible for scientific education of master students (preclinical research)  
 2014-2024 **Member in the Scientific Council of PhD School of Medicine (CSD)**  
 2013-2015 Associate Professor - *Department of Pathology*  
 From 2013 Scientific supervisor for PhD students (**habilitated doctor**)  
 2012 Founder of the Molecular Oncopathology Laboratory  
 2011-2013 Senior Lecturer- *Department of Pathology*  
 2006-2011 Assistant Professor (Junior Lecturer) - *Department of Pathology*

*Clinical Emergency County Hospital of Targu-Mures, Romania, Department of Pathology*

From 2022 - Member of the Ethical Committee of Clinical Research  
 2021-2024 **Elected Member of the Ethical Council**  
 From 2021- Member of the Emergency Situations Council  
 From 2019 - Member of the HYPEC and Digestive Oncoteams  
 2017 - **Foundation of Molecular Oncopathology Laboratory**  
 From 2018 - Member of the Board of examining in-hospital deaths  
 From 2017- Member of the Board of examining the maternal deaths  
 From 2017- Member of the Medical Council  
 From 2016- **Coordinator of the activity of fellows/residents in Pathology**  
 From 2016- **Director of Clinical Department of Pathology**  
 From 2014- **Consultant GI Pathologist**  
 2010-2014 Specialist in Pathology  
 2006-2010 Fellow/Resident in Pathology

*National Institute of Oncology, Budapest, Hungary, Center of Tumors and Molecular Pathology*

PhD coordinator - International cotutela - 2021-2025; Visiting researcher - 2006-2016

*Seoul University, Guro Hospital, Department of Pathology*

Visiting researcher - 2008-2009

*Hamamatsu University, School of Medicine, Center of Tumors, Japan*

Invited Associate Professor - 2014

*Aurelios Augenzentrum Recklinghausen - Munich, Germany/University of Szeged, Hungary*

PhD coordinator - International cotutela - 2021-2025

*Semmelweis University - Budapest, Hungary*

PhD coordinator – International cotutela – 2020-2025

*Polytechnic University of Bucharest (UPB)*

PhD coordinator – National cotutela – 2021-2024

*Other internships/training programmes:* 2019 – ECCO workshop, Santiago, Chile – inflammatory bowel diseases; 2017 – TataabioCenter, Athens, Greece – next generation sequencing; 2016 - Technical University of Munich, Germany – molecular biology; 2015 – Institute of Pathology, Medical University of Graz, Austria – molecular biology; 2007 – Victor Babes University of Medicine, Timisoara, Romania – immunohistochemistry and angiogenesis.

#### **NATIONAL AND INTERNATIONAL IMPACT**

2023- Research Gate Interest Score 905.1 - higher than 92% of ResearchGate members

2022 – Research Gate score 38.16 - higher than 95% of ResearchGate members

From 2019 – Frontiers journals “loop” – scientific score higher than 99% of Frontiers members

2019 – Publons Academy mentor certificate

From June 2018 – Included in the top 4% most read authors on Academia.edu.

2017, 2018 – Outstanding Contribution in Reviewing – Elsevier Reviewer Recognition

From 2018 – Highly Influential Peer reviewer database - Baishideng Publishing Group

2018-2020 – Certification of excellence in reviewing medical papers – Spandidos Publications

From 2017 – Member of Highly Influential Scientists of Baishideng Publishing Group database.

2017 - Included in the top 25% most cited PlosOne author

2014 - First data in Europe (Medline database) about Maspin protein expression in gastric cancer (only 21 papers were published before, by authors from Asia)

2014 – Designed by Biomed central as “highly accessed published paper”.

**2012 – UNESCO-L’Oréal Laurate – For women in science programme**

2008-2012 - First data in Medline database about Mena protein expression in colorectal cancer, cervical and salivary gland lesions

#### **MEMBER IN PROFESSIONAL SOCIETIES**

2021-present – *European Society of Digital and Integrative Pathology*

2021-present - *Romanian Society for Medical Oncology*

2019-present - *World Academy of Sciences*

2017-present - *American Romanian Academy of Arts and Sciences (ARA)*

2017-present - *European Chron’s and Colitis Organisation (ECCO)*

2016-present - *International Society for IHC and Molecular Morphology (ISIMm)*

2014-present - *Romanian Society for Cell Biology*

2013-present - *European Society for Medical Oncology (ESMO)* – ID 318029

2006-present - *Romanian Society for Morphology and Pathology*

*(Vice-President of Targu-Mures branch from 2019)*

2006-present - *European Society of Pathology (ESP)* – Membership number 0000005589

2016-present - member in the ESP Working Groups: Digestive Diseases, Autopsy Pathology – **reviewer for the abstracts submitted for the 35<sup>th</sup> European Congress of Pathology – Dublin, Ireland;** IT (Computational), Molecular Pathology, Dermatopathology, Soft tissue and Bone Pathology

#### **MAIN ACTIVITIES AND RESPONSIBILITIES**

**1. Research activity (Gastrointestinal Cancer, Epithelial mesenchymal transition, Angiogenesis, Immunohistochemistry, Molecular Pathology, Tumor histogenesis, Targeted therapy)**

**2. Methodological knowledge:** microscopy, digital pathology, In situ Hybridization, PCR analysis

**2. Clinical diagnosis in field of GI Tumor Pathology, especially colorectal and gastric cancer** (Histopathology, Immunohistochemistry, In situ Hybridization, PCR analysis, Sanger sequencing)

**3. Teaching activity:** MD students-Romanian, Hungarian and English classes, PhD students, masters' students, scientific supervisor in MD and PhD theses

**4. Administrative activities:** CEO – Clinical Department of Pathology, Vice-Dean, Research projects - coordinator, coordinator of the Research Center - CCOMT

**Fields of research:** gastrointestinal cancer, targeted oncotherapy, epithelial mesenchymal transition, angiogenesis in tumor and non-tumour lesions, tumor lymphangiogenesis, tumor histogenesis, molecular biology in colorectal and gastric cancers (*MSI, K-ras, BRAF, p53, CDH1, HER-2, Maspin, Mena*), immunohistochemistry, In Situ Hybridization (FISH), Sanger sequencing

#### **EDUCATION AND TRAINING**

##### **Name and type of organization providing education and training:**

University of Medicine and Pharmacy of Targu-Mures, Romania

Clinical County Emergency Hospital of Targu-Mures, Romania

**Date and place:** University of Medicine and Pharmacy of Tîrgu-Mures, Romania,  
Faculty of General Medicine – MD student (1999-2005)

**Responsibilities:** – students' leadership from 1<sup>st</sup> to 6<sup>th</sup> year  
– teaching activity at Chair of Pathology starting with the 5<sup>th</sup> year

**MD thesis:** *Morphological and immunohistochemical study of colorectal carcinoma*. Scientific coordinator: Prof. Ioan Jung, Head of Pathology Department of Clinical County Emergency Hospital of Tîrgu-Mures, Romania – 2005

**Diploma:** MD (2005). University of Medicine and Pharmacy of Tîrgu-Mures

**Qualification:** Medical doctor (MD) – September 2005  
Resident/Fellow in Pathology - November 2005  
– passed the National Residential Exam (certificate no 107/2005)

**Date and place:** University of Medicine and Pharmacy of Tîrgu-Mures, Romania - Doctoral School  
PhD student (2005-2008)

**PhD thesis:** *Correlation between classical and modern prognostic factors, angiogenesis and lymphangiogenesis in colorectal carcinomas*. Scientific supervisors: Prof. Ioan Jung, Head of Pathology Department and of Doctoral School of University of Medicine and Pharmacy of Tîrgu-Mures, Romania and Prof. Zoltan Szentirmay, Head of Department of Pathology at National Institute of Oncology, Budapest, Hungary

**Diploma:** PhD (2008), graduated with "*summa cum laudae*"  
Prize of '*Best Romanian PhD thesis in field of medicine*' (CNCSIS, 2010)

**Qualification:** MD, PhD (December 2008)

**Date:** University of Medicine and Pharmacy of Tîrgu-Mureş, Doctoral School –  
Postdoctoral researcher (2008-2013)

**Habilitation thesis:** *The role of molecular pathology in the targeted therapy of cancer*

**Diploma:** Habilitated Doctor (2013)



**Qualification:** MD, PhD, Habilitated Doctor in Medical Sciences,  
Scientific supervisor for PhD students (July 2013)

**Number of coordinating PhD students:** 2013-2023 - 10 in training and 5 PhD students get the PhD title

**Date and place:** Romanian National School of Public Health (2013-2014)

**Diploma/Qualification:** Certificate of Complementary Studies - Management of Public Health  
Romanian Ministry of Health – Certificate No C-035843/24.09.2014

**Name and Address of Employer**

1. George Emil Palade University of Medicine, Pharmacy, Science and Technology;  
540139 Gheorghe Marinescu 38 street, Targu-Mures, Romania Tel: (40-265) 21 31 27  
Fax: (40-265) 21 04 07 E-mail: [rectorat@umfst.ro](mailto:rectorat@umfst.ro), Website: <http://www.umfst.ro>
2. Clinical County Emergency Hospital of Targu-Mures, Romania  
540136 Gheorghe Marinescu 50 street, Targu-Mures, Romania

**Type of business or sector:** medical and academic (academic pathologist, CEO)

**PERSONAL SKILLS AND COMPETENCE**

**Native language:** Romanian

**Other languages:** English (Profex Certificate in Advanced Medical English-C1; Elanguest Certificate –B2)  
French, Italian

**Self assessment**

|         | Understanding |                    | Speaking           |                    | Writing            |
|---------|---------------|--------------------|--------------------|--------------------|--------------------|
|         | Listening     | Reading            | Spoken interaction | Oral presentation  | Writing production |
| English | high level    | high level         | high level         | high level         | high level         |
| French  | high level    | high level         | intermediate level | beginner level     | beginner level     |
| Italian | high level    | intermediate level | intermediate level | intermediate level | beginner level     |

**Social Skills and competences:**

Hobby: travel, poetry, painting, architecture, penguins' life

**Organisational skills and competence**

**Organizing scientific conferences (last year)**

3. The International Conference of PhD students and young doctors, organized during „George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu-Mures, University Days December 11-15, 2023, Targu-Mures, Romania”
4. Scientific Session of University Academic Staff, Târgu Mureş, Romania, organized during „George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu-Mures, University Days December 11-15, 2023, Targu-Mures, Romania”.
5. The Medical Congress of Health and Education. 19-22 October 2023. Brasov, Romania - The scientific committee
6. 2023 - Member in the Scientific Committee of the 35th European Congress of Pathology – reviewer of the abstracts - Autopsy Pathology. Dublin, 9-13 September 2023

**Computer skills and competences**

Competent with all Microsoft Office programmes and experience with HTML, data bases access, Graph Pad InStat, digital counting with Image G NIH's computer assisted programme, MedCalc statistical software, photoshop

## **ADDITIONAL INFORMATION**

### **A. Associate/Academic Editor - Scientific Journals**

2023-2026 – BJC Reports (partner to the British Journal of Cancer) – newly launched – Springer Nature  
2022- Frontiers in Immunology. **IF 7.3** (Q1 web of science - WoS)  
2022-2024- International Journal of Molecular Sciences - Topical Advisory Panel – **IF 5.6** (Q1 WoS)  
2021-2024- Frontiers in Medicine – section Pathology. **IF 3.9** (Q1 WoS - JCI)  
2021-2024 - BMC Cancer – Springer Nature - **IF 3.8** (Q2 - WoS)  
2022-2024 – Analytical Cellular Pathology – Hindawi - **IF 3.2** (Q2 - WoS)  
2020-2024-Life - Basel – Topical Advisory Panel. **IF 3.2** (Q2 - WoS)  
2019-2024-Frontiers in Oncology – section Gastrointestinal: Colorectal Cancers. **IF 4.7** (Q2 WoS)  
2014-2024-Medicine-Lippincott. **IF 1.6** (Q3 WoS)  
2014-2021 – BMC Musculoskeletal Disorders. **IF 1.879** (Q3 WoS-2021)

### **B. Guest Editor-Scientific Journals**

2023/2024 – International Journal of Molecular Sciences – Special Issue “The carcinogenetic potential of Human Papilloma Virus: from experimental studies to targeted therapy” - **IF 5.6** (Q1 WoS)  
2023/2024 – International Journal of Molecular Sciences – Special Issue “Cardiovascular Diseases: Histopathological and Molecular Diagnostics” - **IF 5.6** (Q1 WoS)  
2023/2024 - Frontiers in Bioscience-Landmark – Special Issue – “Gastrointestinal cancer: Pathogenesis, carcinogenesis and targeted therapies”. **IF 3.1** (Q3 – WoS)  
2023/2024 – Current Issues in Molecular Biology – Special Issue – “Future Challenges of Targeted Therapy of Cancers”. **IF 3.1** (Q3 WoS)  
2023 – International Journal of Molecular Sciences – Special Issue – “Advanced Research on Biomarkers in Gastrointestinal Cancer”. **IF 5.6** (Q1 WoS)  
2023 – International Journal of Molecular Sciences – Special Issue – “Future Challenges of Targeted Therapy of Cancers”. **IF 5.6** (Q1 WoS)  
2023-Life - Basel – Special Issue – “Pediatric Gastroenterology Research” **IF 3.253** (Q2 - WoS)  
2022 – Life – Special Issue - “Helicobacter pylori – Interdisciplinary Perspective” **IF 3.2** (Q2 WoS)  
2022 – Gastrointestinal Disorders – Special issue - “Diagnostics, Pathology and Biomarkers of Gastrointestinal Neoplasms”. **IF 0.7**  
2021/2022 – Journal of Oncology – Special Issue – “Colorectal Cancer: from Molecular Genetics to Diagnosis and Therapy”. **IF 4.375** (Q2 WoS) <https://www.hindawi.com/journals/jo/si/965785/>  
2021/2022 – International Journal of Molecular Sciences – Special Issue - “Molecular Diagnostics, Pathology and Biomarkers of Gastrointestinal Neoplasms”. **IF 5.923** (Q1 WoS)  
2020/2021 – Life-Basel – Special Issue - “Serum and tissue biomarkers in Cancer: A Translational Approach” **IF 3.817** (Q2 WoS)  
2020/2021 – Journal of Oncology – Special Issue – “Gastric Cancer: from Molecular Genetics to Diagnosis and Therapy”. **IF 4.375** (Q2 WoS) <https://www.hindawi.com/journals/jo/si/425940/>  
2019/2020 - BioMed Research International. Special Issue in section Oncology - “Tumor Cell Plasticity: From Tumorigenesis to Metastasis”. **IF 3.411** (Q2 WoS)

### **C. Topic Editor-Scientific Journals**

2023/2024 - Frontiers in Oncology – Special Issue/Research Topic in section Gastrointestinal Cancers – “Advanced molecular targets in the diagnosis and treatment of gastrointestinal cancer: Vol II”. **IF 4.7** (Q2 WoS)



2021/2022 - Frontiers in Oncology – Special Issue/Research Topic in section Gastrointestinal Cancers – “Detection and characterization of gastrointestinal (early) cancer”. *IF 6.244 (Q2 WoS)*  
 2020/2021 - Frontiers in Oncology – Special Issue – “Advanced molecular targets in the diagnosis and treatment of gastrointestinal cancer”. *IF 6.244 (Q2 WoS)*


#### **D. Member in Editorial Board-Scientific Journals**

2020-2023 – Life-Basel – Reviewer board. *IF 3.2 (Q2 WoS)*  
 2021 -2023 - Pathology Research and Practice - Elsevier - *IF 2.8 (Q2 WoS)*  
 2022-2023 - Oncology Letters. *IF 2.9 (Q3 web of science)*  
 2023-2024 – Cancer Informatics – Sage. *IF 2.0*  
 2012-2023 - World Journal of Clinical Cases. *IF 1.1 (Q3 web of science)*  
 2021-2023 - Romanian Journal of Morphology and Embryology. *IF 1 (Q4 web of science)*  
 2016-2023 – BMJ Case Reports. *IF 0.9*  
 2023-2024 – Healthcare in Low-Resource Settings. *IF < 0.1*  
 2022-present – Journal of Exploratory Research in Pharmacology. Indexed in Index Copernicus  
 2019-2023 - World Journal of Gastrointestinal Pathophysiology. Indexed in PubMed  
 2019-2024 - Current Drug Research Reviews. Indexed in PubMed  
 2019-2023 - World Academy of Sciences Journal. Spandidos Publications. Indexed in Scopus (Elsevier)  
 2017-2022-Medicinski Glasnik-Indexed in Scopus  
 2015-2022 - Journal of Dermatological Research – Indexed in Google Scholar  
 2015-2023 – Cancer Translational Medicine - Wolters Kluwer- Indexed in EBSCO  
 2014-2023 – Acta Marisiensis – seria Medical. Indexed in Scopus and EBSCO  
 2017-2018-Current Chemical Genomics & Translational Medicine-Indexed in PubMed  
 2016-2017-New Horizons in Clinical Case Reports – Indexed in Scopus  
 2016-2017 – Clinics in Oncology – Indexed in Indexed in ICMJE, Publons, Crossref  
 2013-2017 – Ederium Journal of Pathology – Indexed in J-Gate  
 2013-2017 – Global Journal of Oncologists – Savvy Press – Indexed in DRJI  
 2010-2011 - Journal of Cancer Research and Experimental Oncology

#### **E. PUBLICATIONS**

|                                                                                     |                                                                                   |
|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Papers in extenso published in WoS-indexed journals.....                            | 157                                                                               |
| Papers in extenso published in BDI-indexed journals.....                            | 37                                                                                |
| Other papers published in extenso .....                                             | 19                                                                                |
| Papers in abstract published in WoS-indexed journals.....                           | 96                                                                                |
| Papers in abstract published and presented at international conferences.....        | 61                                                                                |
| Papers in abstract published and presented at national conferences.....             | 188                                                                               |
| Books and chapters published in books .....                                         | 26                                                                                |
| <b>Total Impact factor (IF) from papers in extenso .....</b>                        | <b>310.32</b>                                                                     |
| <b>Total Influence score from papers in extenso.....</b>                            | <b>130.93</b>                                                                     |
| <b>Total Journal citation indicator (JCI) from papers in extenso-2017-2023.....</b> | <b>45.61</b>                                                                      |
| <b>Total Impact factor from abstracts .....</b>                                     | <b>409.03</b>                                                                     |
| <b>Total Influence score from abstracts.....</b>                                    | <b>154.75</b>                                                                     |
| <b>Citations.....</b>                                                               | <b>2324 - Google Scholar</b>                                                      |
| <b>Hirsh-index.....</b>                                                             | <b>26-Google Scholar/22-ResearchGate/20-web of science/19-Scopus/i10-index 76</b> |

#### **F. FOREIGN STUDY TRIPS (SCHOLARSHIPS)**



1. **Munich, Germany**, June – July 2016 - UEG (United European Gastroenterology) Basic Science Course
2. **Hamamatsu- Japan**, July – August 2014 – Hamamatsu University, School of Medicine, Department of Pathology – Invited Associate Professor
3. **Budapest- Hungary**, February 2013 – National Institute of Oncology, Department of Molecular Biology
4. **Budapest- Hungary**, November 2010/July-August 2011/February 2012/July-August 2012 – National Institute of Oncology, Department of Molecular Biology - project PD 504/2010.
5. **Seoul, South Korea**, November 2008/May -June 2009 – Seoul University, Guro Hospital - project 09/30.05.2008, ANCS, Romania.
6. **Pecs-Hungary**, April 2009 – University of Pecs, Faculty of Medicine, Department of Public Health - project 6CB/2008, ANCS, Romania.
7. **Budapest- Hungary**, August – September 2008/February 2009 – National Institute of Oncology, Department of Molecular Biology - project 7CB/2008, ANCS, Romania
8. **Budapest- Hungary** July 2008 – National Institute of Oncology, Department of Molecular Biology - project TD 355/2008, CNCSIS, Romania
9. **Budapest- Hungary**, August 2007 – National Institute of Oncology, Department of Molecular Biology - project TD 505/2007, CNCSIS, Romania
10. **Budapest- Hungary**, October 2006 – National Institute of Oncology, Department of Molecular Biology - project 227/2006, CEEX, Romania.

## **G. SCIENTIFIC PROJECTS**

### ***H.1. HEAD/TEAM COORDINATOR - NATIONAL GRANTS***

1. **2019** - MC, UEFISCDI – Code: PN-III-P1-1.1-MC-2019-2538. Plasmacytoid carcinomas of the stomach: the immunoprofile highlights the potential targeted therapy of these rare histological variants
2. **2019** – MC, UEFISCDI – Code: PN-III-P1-1.1-MC-2019-2145. Scholarship for participation at the 63rd ECCO Educational workshop.
3. **2018-2022** – Proiect Complex de Cercetare de Frontieră – Romanian National Authority for Scientific research – PN-III-P4-ID-PCCF-2016-0006. GRAPHSENGASTROINTEST/Graphene-based stochastic sensors for molecular diagnosis of upper gastro-intestinal cancer
4. **2018** – MC, UEFISCDI - PN-III-P1-1.1-MC-2018-0233 - Bit's 9th annual World DNA And Genome Day. Molecular classification of carcinomas of the gastrointestinal tract – Practical issues.
5. **2017** – MC, UEFISCDI – Code: PN-III-P1-1.1-MC-2017-1950 – No 536/18.12.2017. Gastric Burkitt lymphoma: a case report and literature review.
6. **2017** – MC, UEFISCDI – Code: PN-III-P1-1.1-MC-2017-0197 – No 524/18.12.2017. 22<sup>nd</sup> World Congress On Advances In Oncology And 20th International Symposium On Molecular Medicine. Pitfalls in evaluation of gastrointestinal specimens: metastases mimicking primary tumors.
7. **2014-2020** - MECS-ANCSI. POC-A1-A1.1.4-E-2015. No 50/2016. ID: P\_37\_673. Technologies of tissue engineering for cardiac valve regeneration. VALVE-REGEN. Coordinator of the team of Pathology
8. **2014-2016** - UMFTGM-PO-CC-02-F01: Molecular particularities of early-staged and advanced-gastric cancer, emphasized in surgical and biopsic specimens of patients from Eastern Europe and Japan
9. **2012-2013** - Unesco-L'Oreal: Initiation of targeted therapy in Romanian patients diagnosed with colorectal cancer. National fellowship



10. **2010-2012** - PD, 504/2010, UEFISCDI: Molecular classification of colorectal cancers and testing of K-ras mutations, mandatory for targeted therapy
11. **2008** - TD, 355/2008, CNCSIS – The correlation between prognostic and predictive factors, angiogenesis, lymphangiogenesis and microsatellite instability in colorectal carcinomas
12. **2008** - MC, 85/2008, CNCSIS - The CD31, Endoglin and VEGF expression in non-metastatic colorectal carcinomas
13. **2007** - MD, 33/2007, CNCSIS: Angiogenesis and lymphangiogenesis in colorectal tumors
14. **2007** - TD, 550/2007, CNCSIS: Classical and modern prognostic factors in colorectal carcinomas

## **H.2. MEMBER IN INTERNATIONAL GRANTS**

1. **2008-2009** – **Romania-South Korea**: 09/2008, ANCS: Angiogenesis in acute respiratory distress syndrome
2. **2008-2009** - **Romania-Hungary, Pecs**: 06/2008, ANCS: Mena immunoexpression in benign, premalignant and malignant epithelial lesions. NEOMENA.
3. **2008-2009** - **Romania-Hungary, Budapest**: 07/2008, ANCS: Molecular classification of carcinomas and lymphomas using genetic methods in order to anticipate the results of treatment and to make an individualizing oncotherapy. NEOLIMF.

## **H.3. MEMBER IN NATIONAL GRANTS**

1. **2024-2025** – PNRR project. Role of HIV-1 matrix protein p17 variants in lymphomagenesis: development of new diagnostic tools and therapeutic approaches.
2. **2022-2023** - INEXT - PNRR project for digital development of the professions of the future – Foundation of the Digital Center of Medical Morphological Sciences
3. **2022-2023** – POCU/826/4/9/138603. Prevention, diagnosis and therapy of cervical cancer in early stages.
4. **2021-2023** – PN-III-P4-ID-PCE2020-1540. Novel C-reactive protein inhibitors and dissociation blockers for therapeutic use in cardiovascular disease
5. **2020-2022** - POS-UMFTGM-CC-19: Parietex mesh particularities
6. **2017-2018** – Hungarian Academy of Science 136/2017 – The epithelial-mesenchymal transition in tumors of the gastrointestinal tract.
7. **2017-2018** - Sapientia Hungariae Alapitvány – “A Collegium Talentum” programme – contract 6677/2017
8. **2016-2020** - MECS-ANCSI. POC-A1-A1.1.4-E-2015. No 51/2016. ID: P\_37\_674. C-reactive protein therapy for stroke-associated dementia. SAD-CRP
9. **2015-2016** - Biosintex SRL. 11379/2015. Analysis of clinical and paraclinical parameters used for improvement of diagnostic and therapeutical management of patients with coxartrosis.
10. **2013-2016** - PN-II-ID-PCE-2012-4-0133 „Neuroprotection and angiogenesis: new molecular factors and delivery systems with potential therapeutic application”.
11. **2014-2016** – POS 2013. Foundation of the Advanced Research Center in field of Pharmaceutical and Medical Research, at University of Medicine and Pharmacy of Tirgu-Mures, Romania. CCAMF.
12. **2014-2015** - POSDRU/159/1.5/S/136893. Identification of the particularities of hereditary and sporadic diffuse gastric cancer through molecular and immunohistochemical examinations. Mentor.

13. **2014-2015** - Treepharm S.A. 1699/2014. The advantages and disadvantages of the ligasurterm techniques.
14. **2013-2015** - POS-UMFTGM-CC-13-01-V01, 15/2013 – Standardization of multimodal therapy of gastric cancer, correlating the sentinel node status with the surgical technique and HER-2 gene amplification
15. **2012-2016** - PN-II-ID-PCCE-2011-2-0036: Stem cell seeded collagen scaffolds for heart valve replacement; cod PN-II-ID-PCCE-2011-2-0036.
16. **2010-2013** - POSDRU/89/1.5/S/60782
17. **2008-2011** - 136/2008, CNCSIS: Mechanisms of cellular signaling implied in angiogenesis induced by Acute Respiratory Distress Syndrome (ARDS).
18. **2008-2011** - 1173/2009, CNCSIS: Pathogenic mechanisms implied in developing of insuliniresistance appeared in infection with Hepatitis C virus. HEPINS.
19. **2007-2008** - 41 GR/2007, CNCSIS: Evaluation of metastasis from sentinel lymph node of breast carcinomas through interdisciplinary and multicentric studies in order to develop a new staging and new treatment
20. **2007-2008** - CP-I/13.09.2007, ANCS: Standardization of European detection and early diagnosis of cervical carcinoma and premalignant cervical lesions. EUROGYNPATh
21. **2007-2010 - Partenership** between Universities of Medicine and Pharmacy of Targu-Mures and Timisoara, Romania. 41-054/2007, ANCS: Prognostic and therapeutic value of tumoral lymphangiogenesis. Anatomic-clinic and experimental study in solid malignant tumors.
22. **2007-2008** - 227/2006, CEEX: Modern methods in diagnosis and research, immunohistochemistry, molecular biology and quality control. MEMODIC.

#### **H.4. EVALUATOR OF NATIONAL GRANTS**

1. **2018-2023** – Romanian National Ministry for Innovation and Scientific Research (ANCS). Funding of Excellency in research, development, and innovation (CDI) - Subprogramme 1.2 – Institutional performance.
2. **2016-2023** – L’Oreal and UNESCO-Romanian branch. Competition for national fellowship “Women in science”.
3. **2019** - Romanian Executive Agency for Higher Education, Research, Development, and Innovation (UEFISCDI). Competition of research collaboration between Romania and France. UEFISCDI PN-III-P3-3.1-PM-RO-FR-2019. Certificate no 25/18.04.2019
4. **2017** – Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. Internal competition for the team grant award. Certificate no 3407/14.03.2017.

#### **H. PROFESSIONAL SCIENTIFIC AWARDS (last five years)**

1. **2023** – International Cancer Foundation (ICF) Registration Scholarship for the ESMO (European Society of Medical Oncology) Immuno-oncology – 6-8 December 2023
2. **2023** – International Cancer Foundation (ICF) Registration Scholarship for the ESMO (European Society of Medical Oncology) European Lung Cancer Congress – 29/03 – 01/04/2023
3. **2023** – International Cancer Foundation (ICF) Registration Scholarship for the ESMO Gynaecological Cancers Congress 2023 – 23-24 February 2023
4. **2023** – ISI/WoS -awarded manuscript - UEFISCDI PN-IV-P2-2.3-PRECISI2023-77770.
5. **2023** – ISI/WoS -awarded manuscript - UEFISCDI PN-IV-P2-2.3-PRECISI2023-77322.
6. **2023** – ISI/WoS -awarded manuscript - UEFISCDI PN-IV-P2-2.3-PRECISI2023-77901.
7. **2023** – ISI/WoS -awarded manuscript - UEFISCDI PN-IV-P2-2.3-PRECISI-2023-76566.

8. **2023 – ISI/WoS -awarded manuscript** - UEFISCDI PN-IV-P2-2.3-PRECISI-2023-71244.
9. **2023 – ISI/WoS -awarded manuscript** - UEFISCDI PN-IV-P2-2.3-PRECISI2023-79089.
10. **2023 Best Published Article** - Annual Conference of the Phd and Post-doc students 2023 – Targu-Mures, Romania. First place.
11. **2022 – Paper selected to be presented at the session dedicated to the best posters – Section: Molecular pathology - The 34th European Congress of Pathology** - Basel, Switzerland – 3-7 September 2022
12. **2021 - Paper selected as “one of the three best posters”** - Gurzu S et al. Transdisciplinary approach of colorectal carcinoma cases using an in-house validated map of lymph node stations. An individualized approach for a better staging. **The European Colorectal Congress** - Saint Gallen, Switzerland – 27 November - 2 of December 2021

#### I. ALUMNI

2022 – Aspen Public Service Leadership Program

2012 – The L’Oreal programme „For Women in Science” – winner at the section Life Sciences

#### J. REVIEWER (last two years)

**2024** – International Journal of Surgery. IF 15.3; Expert Review of Molecular Diagnostics. IF 5.1; Frontiers in Oncology. IF 4.7; Scientific Reports. IF 4.6; Journal of Biomolecular Structure & Dynamics. IF 4.4; World Journal of Traditional Chinese Medicine. IF 4.4; Therapeutic Advances in Gastroenterology. IF 4.2; Heliyon. IF 4; European Journal of Surgical Oncology (EJSO) – IF 3.8; Medical Science Monitor – IF 3.1; Turkish Journal of Hematology. IF 2.6; Pathology Research and Practice. IF 2.8; Journal of Chemotherapy. IF 1.8; Clinical Respiratory Journal. IF 1.7; Turkish Journal of Gastroenterology. IF 1.2; Clinical Medicine Insights-Case Reports. IF 1; BMJ Case Reports. IF 0.9; SAGE Open Medical Case Reports. IF 0.8

**2023** – International Journal of Surgery. IF 15.3; Cancers. IF 5.2; Expert Review of Molecular Diagnostics. IF 5.1; Carcinogenesis. IF 4.7; Frontiers in Oncology. IF 4.7; World Journal of Traditional Chinese Medicine. IF 4.4; Cell Cycle. IF 4.3; Therapeutic Advances in Gastroenterology. IF 4.2; Cancer Medicine. IF 4; Heliyon. IF 4.0; Expert Review of Gastroenterology & Hepatology. IF 3.9; Diagnostics. IF 3.6; International Journal of Immunopathology and Pharmacology. IF 3.5; Pathology Research and Practice. IF 3.25; Diagnostic Pathology. IF 2.6; Future Science OA. IF 2.5; BMC Gastroenterology. IF 2.4; Pharmacogenomics. IF 2.1; GERMS. IF 2.0; Clinical Respiratory Journal. IF 1.7; Arab Journal of Gastroenterology. IF 1.4; Journal of Gastrointestinal Cancer. IF 1.6; Medicine (Baltimore). IF 1.6; Saudi Medical Journal. IF 1.6; Cardiology in the young. IF 1; Oncologie. IF 0.9; BMJ Case Reports. IF 0.9; Malawi Medical Journal. IF 0.8; SAGE Open Medical Case Reports. IF 0.8; Case Reports in Oncology. IF 0.8; Journal of Immunoassay and Immunochemistry. IF 0.727; Clinical Case Reports. IF 0.7; Case Reports in Pathology. IF 0.6; Case Reports in Obstetrics and Gynecology. Indexed in WoS without IF; Acta Medica Marisiensis. Indexed in EBSCO; Onco. Indexed in CNKI and WorldCat; Clinical and Translational Discovery. Indexed in Scopus; BJC Reports. Springer Nature; Journal of Medicine and Life. Indexed in PubMed

Date,  
03/28/2024

Signature,  
Prof. Dr. Habil. Simona Gurzu

